Releases - NattoPharma ASA

View:
 

Found press releases

 

Market Making agreement with Norne Securities

5/6/2013 9:02 AM EST
NattoPharma ASA has entered into a Market Making agreement with Norne Securities AS. The purpose of the agreement is to increase the liquidity of the shares of the Company. The Market Making agreement is in accordance with the standard requirements of the Oslo Stock Exchange and will take effect on 8 May 2013.

MenaQ7® Natural Vitamin K Chosen as Finalist for Nutrition Business Technology A...

4/19/2013 3:20 AM EST
OSLO, NORWAY -- NattoPharma ASA (NATTO: Oslo Axess) has announced that its product, MenaQ7Crystals brand vitamin K2 menaquinone-7 (MK-7), the leading MK-7 ingredient, has been selected as a finalist -- one of three -- for Nutrition Business Technology's "Most Effective Product Development Strategy category, as part of its annual awards program presented at Vitafoods, Europe's leading nutritional and food tradeshow.

NattoPharma Names Key Executive:Eric Anderson joins Vitamin K2 Leader to Develop...

4/4/2013 8:31 AM EST
4th April 2013, Oslo, Norway.  NattoPharma announces the appointment of Eric Anderson as Senior Vice President (SVP) Global Sales & Marketing.
In the newly established role as SVP, Eric Anderson will direct the global sales & marketing platform for NattoPharma’s proprietary products, including the MenaQ7® brand Vitamin K2 portfolio. In addition Anderson will create and maintain the North American headquarters...

NattoPharma Names Key Executive:Eric Anderson joins Vitamin K2 as Mk-7 Leader to...

4/3/2013 6:29 AM EST
3rd April 2013, OSLO, NORWAY – NattoPharma (NATTO: Oslo Axess) announces the appointment of Eric Anderson as Senior Vice President Global Sales & Marketing.
In this newly established role, Anderson will direct the global sales & marketing platform for NattoPharma’s proprietary products, including the MenaQ7® brand Vitamin K2 portfolio. Additionally, Anderson will create and maintain the North American...

MenaQ7® brand Vitamin K2 Shown More Potent than K1in New Human Study

4/3/2013 3:00 AM EST
3rd April 2013 Oslo, Norway.  NattoPharma announces today the publication of a new study on its proprietary MenaQ-7™ brand of Natural Vitamin K2 standardized to MK-7 content.  In the human trial, MenaQ7™ was shown to be a potent inhibitor of anticoagulant activity, a strong indicator of the protective benefits of natural K2 for vitamin k-dependent proteins. Interestingly, in this trial, vitamin K2 was shown to be...

NattoPharma’s MenaQ7® to significantly reduce bone loss and risk for osteoporosi...

3/27/2013 4:42 AM EST
27th March 2013 Oslo, Norway. NattoPharma announced yesterday the publication of a groundbreaking new study on its proprietary MenaQ7® brand of Natural Vitamin K2 standardized to MK-7 content in the leading journal Osteoporosis International.
MenaQ7 supplementation in the study demonstrated not only a preservation of bone loss, but also a significant improvement in the bone strength impact index – the predictor...

MenaQ7® brand Vitamin K2 intake prevents bone loss and improves bone impact stre...

3/26/2013 4:28 AM EST
26th March 2013 Oslo, Norway. NattoPharma announces today the publication of a ground-breaking new study on its proprietary MenaQ7® brand of Natural Vitamin K2 standardized to MK-7 content. The company initiated the three-year clinical intervention study on the effects of MenaQ7 on bone health and it is now available online in the leading journal Osteoporosis International as an Online First Article (DOI...

Financial calendar 2013

11/30/2012 8:22 AM EST
Financial calendar 2013

February 28(th) 2013 - Fourth Quarter Results 2012

May 22(nd) 2013 - First Quarter Results 2013

August 27(th) 2013 - Second Quarter Results 2013

November 26th 2013 - Third Quarter Results 2013

Finansiell Kalender 2013

28. februar 2013 - 4. Kvartal 2012 Resultat

22. mai 2013 - 1. Kvartal 2013 Resultat

27. august 2013 - 2. Kvartal 2013 Resultat

26. november 2013 - 3. Kvartal 2013...

Vitamin K2 Containing Food Product – Patent application no. 09/850,804 (“ex-Unil...

9/18/2012 5:13 AM EST
NattoPharma ASA is pleased to announce that our patent application no. 09/850,804 (“ex-Unilvere”) re. “Vitamin K2 Containing Food product” has been approved and issued in USA by the United States Patent and Trade Office. This will strengthen NattoPharma's IPR and commercial platform in USA significantly. The patent will give NattoPharma a broad coverage on the use of menaquinones (vitamin K2) in the preparation of a...

NattoPharma Announces Expansion of Product Portfolio

9/5/2012 9:26 AM EST
NattoPharma, the worldwide pioneer behind MenaQ7® and documentation of health effects of vitamin K-2, has announced it will expand its product portfolio with new products derived from biotechnology, fermentation and green technology.
While the main focus for NattoPharma until now has been on traditional natural vitamin K2 with extended research and development, the ingredient innovator will now include new...

NattoPharma ASA

NattoPharma ASA is a Norwegian nutraceutical company with exclusive rights to sell and market the branded ingredient MenaQ7®, Natural Vitamin K2. We are investing in clinical science to always be at the cutting edge on v...

View more


  CONTACT  
  • Erik Tjørstad
  • CFO & IR Contact
  • 0047 916 36 395
  • 0047 400 9008
  •  
  • Camilla Lindberg
  • Marketing Manager
  • 0047 90954793
  • 0047 4000 9008
  •